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The transforming growth factor (TGF-β) family of growth factors controls an immense number of cellular responses
and figures prominently in development and homeostasis of most human tissues. Work over the past decades has
revealed significant insight into the TGF-β signal transduction network, such as activation of serine/threonine
receptors through ligand binding, activation of SMAD proteins through phosphorylation, regulation of target genes
expression in association with DNA-binding partners and regulation of SMAD activity and degradation. Disruption
of the TGF-β pathway has been implicated in many human diseases, including solid and hematopoietic tumors. As
a potent inhibitor of cell proliferation, TGF-β acts as a tumor suppressor; however in tumor cells, TGF-β looses
anti-proliferative response and become an oncogenic factor. This article reviews current understanding of TGF-β
signaling and different mechanisms that lead to its impairment in various solid tumors and hematological
malignancies.
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Although our understanding of molecular mechanisms
that underlie cancer development and progression has
increased, cancer remains a significant health concern in
many developed countries. There is a strong require-
ment for new diagnostic and treatment options as well
as elucidation of how cells acquire the six essential phe-
notypes, or hallmarks, necessary to become fully malig-
nant [1]. Pharmacological targeting of cancer hallmarks
may offer new possibilities of effectively treating devel-
opment and/or metastases of human tumors (reviewed
in [2]). Transforming Growth Factor-β (TGF-β) is a key
player in cell proliferation, differentiation and apoptosis.
The importance of this regulation is apparent from the
role of TGF-β in development and consequences of ab-
errant TGF-β signaling in cancer [3]. Nevertheless, it is
still not elucidated how malignant cells overcome the
cytostatic functions of TGF-β or how TGF-β stimulates
the acquisition of cancer hallmarks of developing and
progressing human cancers. In this paper, we review dif-
ferent molecular and cellular mechanisms that lead to
impairment of TGF-β signaling in various solid tumors
and hematological malignancies.* Correspondence: sevcik@med.muni.cz
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distribution, and reproduction in any mediumHistory of TGF-β discovery
In the early 1980s, it had become apparent that cell
growth is controlled by many polypeptides and hor-
mones. A new hypothesis of ‘autocrine secretion’ was
postulated, which suggested that polypeptide growth fac-
tors are able to cause malignant transformation of cells
[4]. A new polypeptide called SGF (Sarcoma Growth
Factor) was discovered in cultures of transformed rat
kidney fibroblasts [5]; soon it became apparent that this
factor is a mixture of at least two substances with differ-
ent functions. They were called Transforming Growth
Factor-α (TGF-α) and Transforming Growth Factor-β
(TGF-β) [6]. TGF-β was further described by Roberts
and Sporn as a secreted polypeptide capable of inducing
fibroblast growth and collagen production [7]. Soon after
its discovery, TGF-β was found to inhibit cell prolifera-
tion as well; thus, a dual role of this cytokine was recog-
nized [8,9].TGF-β family and isoforms
The TGF-β superfamily is composed of a large group of
proteins, including the activin/inhibin family, bone mor-
phogenetic proteins (BMPs), growth differentiation factors
(GDFs), the TGF-β subfamily, and the glial cell line-
derived neurotrophic factor (GDNF) family. This review
will focus solely on the TGF-β family.tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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of species, including invertebrates as well as vertebrates.
TGF-β superfamily is fundamental in regulation of vari-
ous biological processes, such as growth, development,
tissue homeostasis and regulation of the immune system
[10,11].
Beta-type subfamily growth factors are homodimeric
or heterodimeric polypeptides with multiple regulatory
properties depending on cell type, growth conditions
and presence of other polypeptide growth factors. Since
their expression is also controlled by distinct promoters,
their secretion is temporal and tissue specific [12].
There are three known isoforms of TGF-β (TGF-β1,
TGF-β2 and TGF-β3) expressed in mammalian tissues;
they contain highly conserved regions but diverge in sev-
eral amino acid regions. All of them function through
the same receptor signaling pathways [13,14].
TGF-β1, the most abundant and ubiquitously
expressed isoform, was cloned from human term pla-
centa mRNA [15]. In mouse development, Tgf-β1 mRNA
and/or protein have been localized in cartilage, endo-
chondral and membrane bone and skin, suggesting a role
in the growth and differentiation of these tissues [16].
TGF-β2 was first described in human glioblastoma cells.
It was found that TGF-β2 is capable of suppressing inter-
leukin-2-dependent growth of T lymphocytes. Thereby, it
was named glioblastoma-derived T cell suppressor factor
(G-TsF). Physiologically, TGF-β2 is expressed by neurons
and astroglial cells in embryonic nervous system [17]. It is
also important in tumor growth enhancing cell prolifera-
tion in an autocrine way and/or reducing immune-
surveillance of tumor development [18]. Their mature
forms, which consist of the C-terminal 112 amino acids,
TGF-β1 and TGF-β2 share 71% sequence similarity [19].
The third isoform, TGF-β3, was isolated from a cDNA
library of human rhabdomyosarcoma cell line; it shares
80% of amino acid sequence with TGF-β1 and TGF-β2.
Studies on mice demonstrated essential function of Tgf-
β3 in normal palate and lung morphogenesis and impli-
cate this cytokine in epithelial-mesenchymal interaction
[20,21]. Its mRNA is present in lung adenocarcinoma
and kidney carcinoma cell lines; interestingly, umbilical
cord expresses very high level of TGF-β3 [19].
TGF-β synthesis and activation
Mature dimeric form of TGF-β, composed of two mono-
mers stabilized by hydrophobic interactions and disul-
phide bridge, initiates intracellular signaling [22]. The
three TGF-βs are synthesized as pro-proteins (pro-TGF-
βs) with large amino-terminal pro-domains (called la-
tency associated proteins – LAPs), which are required
for proper folding and dimerization of carboxy-terminal
growth-factor domain (mature peptide) [23]. This com-
plex is called ‘small latent complex’ (SLC). After foldingand dimerization, TGF-β dimer is cleaved from its pro-
peptides in trans-Golgi apparatus by furin type enzymes;
however, it remains associated with its pro-peptide
through noncovalent interactions, creating ‘large latent
complex‘ (LLC). Most cultured cell types release latent
TGF-β into extracellular matrix as LLC which in
addition includes a 120–240 kDa glycoprotein called la-
tent TGF-β binding protein (LTBP) [24]. LTBP is com-
posed primarily of two kinds of cysteine-rich domains:
EGF-like repeats (most of which are calcium-binding)
and eight-cysteine domains [25]. LTBP participates in
the regulation of latent TGF-β bioavailability by addres-
sing it to the extracellular matrix (ECM) [26]. Non-
active TGF-β stays in ECM; its further activation is a
critical step in the regulation of its activity (Figure 1).
A number of papers have reported TGF-β activation
by retinoic acid and fibroblast growth factor-2 (FGF-2)
in endothelial cells [27,28], or by endotoxin and bleomycin
in macrophages [29]. Further, a variety of molecules is
involved in TGF-β activation. Proteases including plasmin,
matrix metaloproteases MMP-2 and MMP-9, are TGF-β
activators in vitro [30,31]. Other molecules involved in the
mechanism of activation are thrombospondin-1 [32],
integrins, such as αVβ6 or αVβ8 [33,34], or reactive oxygen
species (ROS).
Moreover, latent TGF-β present in conditional
medium is activated by acid treatment (pH 4.5) in vitro
[35]. In vivo, a similar pH is generated by osteoclasts
during bone resorption. Since the bone matrix deposited
by osteoblasts is rich in latent TGF-β, the acidic envir-
onment created by osteoclasts in vitro might result in la-
tent TGF-β activation [36].
TGF-β receptors
In most cells, three types of cell surface proteins mediate
TGF-β signaling: TGF-β receptor I (TβRI), II (TβRII)
and III (TβRIII) [13,37]. Out of these three receptors,
TβRIII, also called betaglycan, is the largest (250–
350 kDa) and most abundant binding molecule. This
cell-surface chondroitin sulfate / heparan sulfate proteo-
glycan is expressed on both fetal and adult tissues and
most cell types [38]. Endoglin (CD105) was shown to act
as type III receptor for TGF-β as well [39]. Endoglin is a
membrane, an RGD-containing glycoprotein, which is
expressed in a limited set of cell types, primarily vascular
endothelial cells, several hematopoietic cell types, bone
marrow stromal cells and chondrocytes. Its expression
strongly increases in active vascular endothelial cells
upon tumor angiogenesis [40-42]. Moreover, in normal
brain, it was found to be expressed in the adventitia of
arteries and arterioles, and it is expressed on several
types of tumor cells, such as invasive breast cancers
and cell lines or renal cell carcinoma [43-45]. Although
betaglycan and endoglin are co-receptors not directly
Figure 1 TGF-β synthesis and activation. TGF-βs are synthesized as inactive precursors that contain pre-region (Signal peptide) and pro-region
(N terminal peptide - LAP). Processing of inactive form starts with proteolytic cleavage that removes signal peptide from pre-pro-TGF-βs form.
After dimerization, TGF-βs are cleaved by proteases (eg. Furin) into C-terminal mature peptides and N-terminal LAP (Latency Associated Peptide).
TGF-βs with LAP form small latent complexes (SLP) that are transported to extracellular matrix where can further covalently bind to latent TGF-β
binding protein (LTBP) to form a large latent complexes (LLC). LTBP is able to connect inactive TGF-β forms to ECM proteins. This interaction is
further supported by covalent transglutaminase-induced (TGase) crosslinks. Activation of TGF-β starts with release of LCC from ECM by proteases.
Then, the mature protein is cleaved from LTBP, which is provided in vitro by acidic condition, pH or plasmin or in vivo by thrombospondin (TSP).
Once the active TGF-β family member is released from the ECM, it is capable of signaling.
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kinase domain, they can control access of TGF-β to
TGF-β receptors and consequently modulate intracellu-
lar TGF-β activity [46,47]. Betaglycan binds all three
isoforms of TGF-β, with higher affinity for TGF-β2;
however, endoglin binds TGF-β1 and -β3 with constant
affinity and has only weak affinity for TGF-β2 [39,48].
TβRI and TβRII mediate signal transduction. Both
receptors are transmembrane serine/theronine kinases,
which associate in a homo- or heteromeric complex and
act as tetramers. They are organized sequentially into an
N-terminal extracellular ligand-binding domain, a trans-
membrane region, and a C-terminal serine/threonine
kinase domain. The type II receptors range from 85 to
110 kDa, while the type I receptors are smaller and their
size ranges from 65 to 70 kDa [49]. Moreover, TβRI con-
tains a characteristic, highly conserved 30 amino acids
long GS domain in the cytoplasmic part, which needs tobe phosphorylated to fully activate TβRI [36]. TβRII con-
tains 10 bp polyadenine repeat in the coding region of
the extracellular domain. This region is frequently a tar-
get of changes leading to frameshift missense mutations
or early protein terminations that result in truncated or
inactive products [50].
TGF-β receptors activation
Bioactive forms of TGF-βs are dimers held together by
hydrophobic interactions and, in most cases, by an inter-
subunit disulfide bond as well. The dimeric structure of
these ligands suggests that they function by bringing to-
gether pairs of type I and II receptors, forming heterote-
trameric receptor complexes [51]. Binding of TGF-β to
extracellular domains of both receptors also induces
proper conformation of the intracellular kinase domains.
These receptors are subject to reversible post-transla-
tional modifications (phosphorylation, ubiquitylation and
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receptors as well as SMAD and non-SMAD pathway
activation.
Receptor phosphorylation activates TGF-β signaling
pathway – the ligand binds to TβRII first, followed by
subsequent phosphorylation of a Gly-Ser regulatory re-
gion (GS-domain) within TβRI. This leads to incorpor-
ation of TβRI and formation of a large ligand-receptor
complex that consists of dimeric TGF-β ligand and two
pairs of TβRI and TβRII [52]. The TGF-β receptor com-
plex is extremely stable upon solubilization [53]. TGF-β1
and TGF-β3 bind to TβRII without participation of type
I receptor, whereas TGF-β2 interacts only with combin-
ation of both receptors (reviewed in [54]). Although lig-
and binding may induce autophosphorylation of TβRII
cytoplasmic domain, signaling in the absence of TβRI
has not been reported [49]. TβRIII betaglycan promotes
binding of TGF-β2 to TβRII, since the affinity of TGF-
β2 to TβRII is low in the absence of betaglycan [46].
Endoglin binds TGF-β1, TGF-β3 but not TGF-β2 in the
presence of the TβRI and TβRII. In some cell types,
endoglin was found to inhibit TGF-β signaling – for
example in chondrocytes, it enhances TGF-β1-induced
SMAD1/5 phosphorylation but inhibits TGF-β1-induced
SMAD2 phosphorylation [55].
Ubiquitylation and ubiquitin-mediated degradation de-
fine stability and turnover of receptors. Ubiquitylation
occurs through sequential actions of E1, E2 and E3 ubi-
quitin ligases that provide specificity in the ubiquityla-
tion process [56]. The E3 ubiquitin ligases such as
Smurf1 and Smurf2 (SMAD ubiquitylation-related factor
1 and 2) regulate the stability of TβRI and heteromeric
TGF-β receptor complex [57,58].
Sumoylation, similarly to ubiquitylation, requires E1,
E2 and E3 ligases which results in SUMO polypeptide
attachment. Although sumoylation has not been
observed for any other transmembrane receptor kinases,
it was shown to modify TβRI function by facilitating the
recruitment and phosphorylation of SMAD3 [59].
TGF-β receptors are also constitutively internalized via
clathrin-dependent or lipid-raft-dependent endocytic
pathways (reviewed in [60]).
TGF-β signaling
SMAD proteins
The SMAD proteins are the only known latent cytoplas-
mic transcription factors that become directly activated
by serine phosphorylation at their cognate receptors.
SMADs can be classified into 3 groups based on their
function: the receptor-regulated SMADs (R-SMADs),
SMAD1, SMAD2, SMAD3, SMAD5 and SMAD8; the
common SMAD (Co-SMAD), SMAD4, and the inhibi-
tory SMADs (I-SMADs), SMAD6 and SMAD7 (reviewed
in [61]).R-SMADs and Co-SMAD consist of a conserved MH1
domain (Mad-homology-1) and C-terminal MH2 do-
main (Mad-homology-2), which are connected by a
’linker’ segment. The C-terminal domain promotes tran-
scriptional activity, when fused to a heterologous DNA
binding domain [62]. On the contrary, I-SMADs contain
only the highly conserved MH2 domain. The MH1 do-
main is responsible for binding to DNA; however, the
MH2 domain contains hydrophobic patches also called
hydrophobic corridors that allow binding to nucleopor-
ins, DNA-binding cofactors and various cytoplasmic
proteins, as well as interaction with receptors. Both
domains can interact with sequence-specific transcrip-
tion factors. SMAD3 and SMAD4 bind with their MH1
domain to SMAD-binding elements (SBE) on DNA,
whereas the common splice form of SMAD2 does not
bind to DNA (reviewed in [63]).
I-SMADs function as intracellular antagonists of R-
SMADs. Through stable interactions with activated
serine/threonine receptors, they inhibit TGF-β family
signaling by preventing the activation of R- and Co-
SMADs. I-SMADs regulate activation of R-SMADs via
binding with their MH2 domain to TβRI, thereby com-
peting with R-SMADs and preventing R-SMADs phos-
phorylation [64]. SMAD6 is also able to compete with
SMAD4 for heteromeric complex formation with acti-
vated SMAD1 [65]. Whereas SMAD6 appears to prefer-
entially inhibit BMP signaling, SMAD7 acts as a general
inhibitor of TGF-β family signaling. Another possible
mechanism of inhibition signaling transduction by I-
SMADs is facilitated by HECT type of E3 ubiquitin lig-
ase Smurf1 and Smurf2 [57,58].
Canonical signaling
The SMAD pathway is the canonical signaling pathway
that is activated directly by the TGF-β cytokines
(Figure 2). TβRI recognizes and phosphorylates signaling
effectors – the SMAD proteins. This phosphorylation is
a pivotal event in the initiation of TGF-β signal, followed
by other steps of signal transduction, subjected to both
positive and negative regulation.
R-SMAD binding to the type I receptor is mediated by
a zinc double finger FYVE domain containing protein
SARA (The SMAD Anchor for Receptor Activation).
SARA recruits non-activated SMADs to the activated
TGF-β receptor complex [66]. However, TMEPAI
(TransMembranE Prostate Androgen-Induced gene/pro-
tein), a direct target gene of TGF-β signaling, perturbs
recruitment of SMAD2/3 to TβRI and thereby partici-
pates in a negative feedback loop to control the duration
and intensity of SMADs activation [67]. Receptor-
mediated phosphorylation of SMAD2 decreases the af-
finity of SMAD2 to SARA, leading to dissociation from
SARA [68]. Afterwards, phosphorylated complex of
Figure 2 TGF-β canonical signaling pathway. After ligand binding, TGF-β receptors dimerize and phosphorylate intracellular SMAD proteins.
Complex of SMAD2 and/or SMAD3 becomes phosphorylated by TβRI and forms a complex with SMAD4 which is subsequently transported into
the nucleus where it binds with specific transcription factors (TF) and induces a transcription of TGF-β dependent genes.
Kubiczkova et al. Journal of Translational Medicine 2012, 10:183 Page 5 of 24
http://www.translational-medicine.com/content/10/1/183SMAD2/3 forms a higher-order complex with SMAD4
and moves to the nucleus. At this point, Smurf1 inter-
acts with R-SMADs in order to trigger their ubiquityla-
tion and degradation and hence their inactivation [69].
Further, it was found that Smurf1 and Smurf2 facilitate
the inhibitory effect of I-SMADs. Smurf2 binding in the
nucleus to SMAD7 induces export and recruitment to
the activated TβRs, where it causes degradation of
receptors and SMAD7 via proteasomal and lysosomal
pathways [57]. Smurf1 (specific for BMP-SMADs) also
interacts with SMAD7 and induces SMAD7 ubiquityla-
tion and translocation into the cytoplasm [58].
For proper translocation to the nucleus, the SMADs
contain a nuclear localization-like sequence (NLS-like;
Lys-Lys-Leu-Lys) that is recognized by importins [70].
Interestingly, the nuclear translocation of SMADs was
also described in vitro to occur independently of added
importin-like factors, because SMAD proteins can dir-
ectly interact with nucleoporins, such as CAN/Nup214
[71,72]. Complex of SMAD2/3 and SMAD4 is retained
in the nucleus by interactions with additional protein
binding partners and DNA. Dephosphorylation and dis-
sociation of SMAD transcriptional complexes are
thought to end this retention, allowing export of R-
SMADs out of the nucleus [73].
Different protein binding partners provide another
venue for regulatory inputs controlling the activity of
SMADs. Each SMAD-partner combination targets a par-
ticular subset of genes and recruits either transcriptionalco-activators or co-repressors. Members of many DNA-
binding protein families participate as SMADs cofactors,
such as FOX, HOX, RUNX, E2F, AP1, CREB/ATF, Zinc-
finger and other families. The SMAD cofactors differ in
various cell types, thereby determining the cell-type
dependent responses [63]. By association with DNA-
binding cofactors, SMADs reach target gene specificity
and target specificity. Stimulation of various cells by
TGF-β leads to rapid activation or repression of a few
hundred genes; possibly, the pool of activated SMAD
proteins is shared among different partner cofactors
[74,75].
On chromatin level, SMADs can recruit histone acet-
yltransferases. Several studies revealed that TGF-β pro-
teins influence transcription of different genes through
interaction of the MH1 domain of SMADs with
sequence-specific transcription factors and co-activators
CBP and p300. CBP and p300 interact with SMAD1,
SMAD2, SMAD3 and SMAD4 in vitro and in vivo, and
the interaction between the SMADs and CBP/p300 is
stimulated in response to TGF-β [76-79]. Moreover, his-
tone deacetylases and chromatin remodeling complexes
are also involved in SMAD regulation. In this way,
SMADs functionally interact with a variety of transcrip-
tion factors and regulate diverse signaling pathways as
well (reviewed in [80]).
SMADs act as sequence specific transcription factors;
however, they can regulate cell fate by alternative
mechanisms. Recent data indicate that R-SMADs
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sing complex to regulate miRNA processing in a ligand-
dependent and RNA-sequence specific manner. So far,
more than 20 TGF-β/BMP-regulated miRNAs (T/B-
miRs) have been described [81,82].Non-SMAD signaling
Diversity of TGF-β signaling in cells is determined not
only by various ligands, receptors, SMAD mediators or
SMAD-interacting partners, but also by the ability of
TGF-β to activate other signaling pathways (Figure 3).
TGF-β can indirectly participate in apoptosis, epithelial
to mesenchymal transition, migration, proliferation, dif-
ferentiation and matrix formation (reviewed in [83]). It
activates various branches of mitogen-activated protein
kinases (MAPK) pathway, such as ERK1/ERK2, Jun-N
terminal kinase (JNK) and p38 and PI3K kinases [84]. In
response to TGF-β, both SMAD-dependent and SMAD-
independent JNK activations are observed [85]. SMAD-
independent activation of p38 was observed in mouse
mammary epithelial NMuMG cells with mutant TβRI
[86].
Other pathways influenced by TGF-β are the growth
and survival promoting pathway AKT/PKB, the small
GTP-binding proteins RAS, RHOA, RAC1 as well as
CDC42 and mTOR [87-89]. TGF-β participates in medi-
ating activation of protein tyrosine kinases FAK, SRC
and ABL, particularly in mesenchymal or dedifferen-
tiated epithelial cells [90-92]. TGF-β also influences NF-
κB signaling and Wnt/β-catenin pathway [93].Figure 3 TGF-β non-canonical signaling pathway. After ligand binding,
malignant cells, such as Notch signaling, MAP kinases, AKT/PKB pathway, G
pathway.Role of TGF-β in tumors
In tumors, TGF-β can be either a proto-oncogene or a
tumor suppressor, depending on cell context and tumor
stage [94]. Cancer cells often evade growth inhibition
effects of TGF-β, while leaving intact TGF-β-mediated
cellular responses that promote tumor progression.
Importantly, the use of mouse models has enabled the
elucidation of the dual role of TGF-β in cancer
(reviewed in [95]). As homozygous deletions of Tgf-β1,
Tgf-β2, Tgf-β3, TβRI and TβRII are lethal in mice, ma-
nipulation of TGF-β pathway was achieved mainly
through transgene expression or conditional null muta-
tions in vivo [96]. The dual role of TGF-β was shown on
a set of experiments with mice skin cancer. The first
study demonstrated that TGF-β1 expression targeted to
keratinocytes inhibits benign tumor outgrowth; however,
later it enhances malignant progression rate and pheno-
type of the benign papillomas [97]. Study on transgenic
mice overexpressing a dominant negative TβRII in the
basal cell compartment and in follicular cells of the skin
complemented previous results. In non-irritated epider-
mis of transgenic mice, proliferation and differentiation
were normal; however, during tumor promotion, trans-
genic mice showed an elevated level of proliferation in
the epidermis [98]. Furthermore, using mice with indu-
cible expression of TGF-β1 in epidermis confirmed the
dual role of TGF-β [99,100].
TGF-β as a tumor suppressor
The most critical effect of TGF-β on target cells is sup-
pression of proliferation. Its growth inhibitory functionseveral different branching signaling pathways can be activated in
TP-binding proteins pathway, PTK pathway, NF-κB and Wnt/β-catenin
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tion of c-Myc and cyclin-dependent kinases (CDKs) and
to enhance expression of the CDK inhibitors p15INK4B
[101] [102] and p27KIP1 [103].
Cellular responses to TGF-β depend on cell type and
physiological conditions. TGF-β stimulates various mes-
enchymal cell types, including fibroblasts; however, it is
a potent inhibitor of epithelial, endothelial, neural cells
and hematopoietic cells, including immune cells [10].
Central function of TGF-β is inhibition of cell cycle pro-
gression by regulating transcription of cell cycle regula-
tors (Figure 4). Anti-proliferative responses can be
induced at any time during cell cycle division; yet, they
are effective only in G1 phase. Once a cell is committed
to enter replication, it will continue to double its DNA,
divide and then arrest when entering the following G1
phase. At this point, TGF-β mediates cell cycle arrest by
suppressing expression and function of c-Myc, members
of the Id family inhibitors and CDKs and enhancing ex-
pression of CDK inhibitors, such as p15INK4B, p21CIP1
and p27KIP1 [104,105].
TGF-β induces the expression of the CDK inhibitor
p15INK4B in a variety of cell types. p15INK4B is a member
of the INK4 family of CDK inhibitors, which binds to
CDK4 and CDK6 subunits, inactivates their catalytic ac-
tivity and prevents cyclin D-CDK4/6 complex formation
[101,106]. Furthermore, TGF-β can induce expression of
p21CIP1 in several cell types [107,108]. Other CDK in-
hibitory responses, observed in several cell types afterFigure 4 Role of TGF-β in regulation of cell cycle. Physiologically, TGF-β
and represses expression of c-Myc. p15INK4B is able to prevent cyclin D-CDK
from cyclin D-CDK4/6 complexes. These CIP/KIP inhibitors are subsequently
inhibit cell cycle. Moreover, low levels of c-Myc allows for TGF-β induced pexposure to TGF-β, are inhibition of CDK4 expression
and down-regulation of CDC25A expression [109].
Low levels of c-Myc allow for TGF-β induced tran-
scription of p15INK4B and p21CIP1 genes. Decreased ex-
pression of c-Myc in keratinocytes is mediated by
SMAD3 in association with transcription factors E2F4
and E2F5, p107 co-repressor and SMAD4 [110]. On the
other hand, down-regulation of Id proteins in epithelial
cells is due to activated SMAD3 that induces activating
transcription factor (ATF) expression and then together
with ATF directly represses the Id promoter [104].
TGF-β as a tumor promoter
TGF-β acts as tumor suppressor in normal epithelium; it
inhibits cell proliferation and induces apoptosis. Yet,
during tumor progression, sensitivity to these effects of
TGF-β is frequently lost and, in later stages, TGF-β sig-
naling has pro-oncogenic function. Several activities
have been described to TGF-β that would favor tumor
progression [111].
Mutations in signaling components
Malignant cells become resistant to suppressive effects
of TGF-β either through mutation and/or functional in-
activation of TGF-β receptors or by downstream altera-
tions in the SMAD-signaling pathway. During late stages
of tumor progression, TGF-β acts as tumor promoter
and is often over-expressed in many cancers. Elevated
plasma level of TGF-β1 was observed in hepatocellularis a potent inhibitor of cell cycle; it induces expression of p15INK4B
4/6 complex formation; moreover, it displaces p21CIP1 and p27KIP1
able to inactivate other complexes of G1 and S phase and thereby
15INK4B and p21CIP1 transcription.
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cers and correlates with poor prognosis [112].
Mutations in downstream TGF-β signaling compo-
nents cause variable attenuations or complete loss of ex-
pression; these mutations, which have been detected in
many common tumors, affect TGF-β signal transmission
that potentially results in human cancer development
and progression. In particular, TβRI, TβRII, SMAD2 and
SMAD4 are frequently lost, mutated or attenuated
(gene/LOH/expression). Inactivation of TβRII leads to
increased tumor spreading and metastasis in a variety of
carcinomas, including colon [113], breast [114], pancre-
atic [115], intestinal [116] or head and neck squamous
cell carcinoma (HNSCC) [117]. Also, deregulated ex-
pression or aberrant function of Smurf1 and 2 was
described. Several human carcinoma cell lines such as
colon HT-29, breast MDA-MB-231, gastric MKN-1 and
ovarian OVCAR-5 display high levels of one or more
E3 ligases, including Smurf2 [118,119]. Moreover, in
esophageal squamous carcinoma, high expression levels
of Smurf2 associated with low levels of SMAD2 phos-
phorylation were detected [120]. Furthermore, TGF-β
pathway is modulated by epigenetic mechanisms, such as
transcriptional repression of TβRII, DNA methylation of
TβRI and TβRII and histone modifications [121-123].
TGF-β in tumor microenvironment and metastases
Tumor metastases accounts for the majority of cancer
associated deaths. Recent evidence strongly suggests that
tumor microenvironment is essential in this process. It
consists of tumor cells and a variety of immune cells,
which infiltrate into tumors. This dynamic microenvir-
onment is not only important for cross-talk with tumor
cells or escape of tumor from host immune surveillance,
but it also induces formation of new blood vessels and
invades the vasculature. Areas of hypoxic tissue are
thought to drive genomic instability and alter DNA
damage repair [124]. Recent studies suggest that TGF-β
is one of the critical regulators of inflammation; it is
thought that tumor metastasis is a coordinated process
between tumor cells and host cells through inflamma-
tion [125]. However, it seems that different mechanisms
are implemented in different tumor type.
TGF-β as a proto-oncogene is important in stromal-
epithelial cross-talk, as was shown for the first time in
mouse experiments, where deletion of the TβRII in stro-
mal fibroblasts resulted in transformation of adjacent
epithelia of prostate and forestomach. Moreover, in this
model, hepatocyte growth factor (HGF) was up-
regulated and complementary activation of the HGF re-
ceptor MET was detected in tissues where TβRII had
been ablated, which implicates this paracrine signaling
network as a potential mechanism for regulation of
carcinoma development [126]. Further experimentperformed on these mice revealed that mice fibroblasts
have up-regulated expression of growth factors and
increased proliferation of mammary cancer cells [127].
Together, it indicates that TGF-β responses mediated by
stromal fibroblasts can regulate carcinoma initiation and
progression of adjacent epithelium in vivo and in vitro.
Interestingly, it was found that TGF-β in breast cancer
favors metastasis to lungs. TGF-β stimulation of mam-
mary carcinoma cells in tumor microenvironment, be-
fore they enter circulation, primes these cells for seeding
of lungs through a transient induction of angiopoetin-
like4 (Angptl4) via canonical signaling pathway [128].
TGF-β is involved in regulation of chemokines and che-
mokine receptors which take part in inflammatory cells
recruitment. The loss of TβRII in breast cancer cells can
enhance recruitment of F4/80+ cells to tumor micro-
environment and increase the expression of pro-
inflammatory genes, including CXCL1, CXCL5 and
PTGS2 (cyclooxygenase-2). Further, in vitro treatment of
carcinoma cells with TGF-β suppressed the expression
of CXCL1, CXCL5 and PTGS2 [129].
Different mechanism was observed in gastric carcin-
oma, where SMAD-dependent TGF-β pathway, in col-
laboration with PKC-δ expression and phosphorylation
and integrin expression and activation, regulates cell in-
vasion and cell spreading [130].
Beside the effects already mentioned, TGF-β is broadly
implemented in induction of epithelial-to-mesenchymal
transition [131]. The NBT-II cell line, derived from a
chemically induced rat bladder carcinoma, forms epithe-
lial colonies that can be converted into migratory mes-
enchymal cells within a few hours by adding Tgf-β and
other factors, such as Fgf1, Fgf7, Fgf10, Egf, Igf1, Igf2 or
Hgf [132].
TGF-β as a regulator of immune cells
The tumor microenvironment is filled with various in-
flammatory cells, including myeloid cell subpopulations,
T cells and B cells. TGF-β is one of the most potent en-
dogenous negative regulators of hematopoiesis. It modu-
lates proliferation, differentiation and function of all
types of lymphocytes, macrophages and dendritic cells,
thus regulating the innate, non-antigen-specific as well
as antigen-specific immunity [133].
TGF-β is involved in normal B cells maturation and
differentiation, such as regulation of expression of cell-
surface molecules, inhibition of IgM, IgD, CD23 and the
transferrin receptor and induction of MHC class II ex-
pression on pre-B cells and mature B cells [134].
In T cells, TGF-β regulates maturation; for example, it
is released by regulatory T cells and inhibits the Ag-
specific proliferation of naive CD4+ cells from T cell re-
ceptor (TCR) [135]. TGF-β1 also inhibits aberrant T
cell expansion by maintaining intracellular calcium
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response by Ca2+-independent stimulatory pathways
[136].
In myeloid cells, such as macrophages and monocytes,
TGF-β1 is mostly suppressive, it inhibits cell prolifera-
tion and down-regulates production of reactive oxygen
and nitrogen intermediates; however, it is able to en-
hance some other activities of myeloid cells. TGF-β1 can
be recognized by monocytes and macrophages as a
chemotactic factor; it induces direct monocytes migra-
tion in vitro [137].
TGF-β pro-metastatic and pro-inflammatory effects
are regulated via nuclear factor kappa B (NF-κB), the
master regulator of inflammation and a regulator of
genes that controls cell proliferation and cell survival.
TGF-β1 is a negative regulator of NF-κB activation, as
was shown in the gut; it directly stimulates IκB-α pro-
moter transcriptional activity in vitro. However, SMAD7
maintains high NF-κB activity by blocking TGF-β1 sig-
naling [138].
Targeting the TGF-β signaling pathway
As the signaling pathway deregulations are responsible
for cancer initiation and progression, interrupting the
tumor promoter properties of TGF-β signaling would be
an attractive therapeutic strategy, without altering
physiologic tumor suppressor functions exhibited in
early stages of tumorigenesis. Strategies such as using
monoclonal TGF-β-neutralizing antibodies, large mol-
ecule ligand traps, reducing translational efficiency of
TGF-β ligands using antisense technology and antagon-
izing TGF-β receptor I/II kinase function by small mol-
ecule inhibitors are the most prominent methods being
explored today [139,140]. Furthermore, studies have
shown that combined treatment with tumor cell vac-
cines and antisense TGF-β therapy reduced tumor size
and increased survival benefit [141,142]. Preclinical stud-
ies also show that TGF-β inhibition can augment thera-
peutic efficacy of cytotoxic agents [143]. However, as
there are still potential limitations and risks of TGF-β
targeted therapy, caution must be given as to when, how
and how much therapy would be beneficial or how
much toxicity will be induced by chronically adminis-
tered therapy. However, daily administration of a high
dose of neutralizing TGF-β antibody in adult mice for
12 weeks and a lifetime exposure to soluble TβRII
(sTβRII) in transgenic mice did not significantly affect
their health. This suggests that anti-TGF-β treatments
are likely to be safe [144].
TGF-β in solid tumors
Brain tumors
TGF-β has a suppressive role in physiological develop-
ment of the central nervous system (CNS): all TGF-βisoforms and receptors necessary for TGF-β signal trans-
duction are detected in developing as well as adult CNS
[145].
The most aggressive type of primary brain tumors,
glioblastoma multiforme (GBM), is characterized by
poorly differentiated and highly proliferating cells that
originate from glial cells [146,147]. Here, the release
from cytostatic TGF-β effect is explained by a broad
range of inactivating mutations in the TGF-β signaling
pathway. Several studies describe mutations in TβRI and
TβRII in adenomas and gliomas [148,149] as well as cor-
relation between higher expression of TβRI and TβRII
with more aggressive glioma cell lines and tumors
[150,151]. Moreover, high levels of TGF-β indicate that
TGF-β is able to induce its own expression and thereby
create a malignant autocrine loop and control glioma-
cell proliferation [152]. Alterations of SMAD protein
levels and activation were reported in brain tumor cell
lines and patient samples. In glioma cell lines, SMAD3
level and SMAD2 nuclear translocation was lower in 9
out of 10 cell lines [153]. Kjellman et al. reported that
SMAD2, SMAD3 and SMAD4 mRNA levels were
reduced in GBM samples in comparison to normal brain
samples, astrocytomas and anaplastic astrocytomas
[150]. Nevertheless, these data are controversial to a
study in which higher phospho-SMAD2 (p-SMAD2)
level correlated with higher grade of glioma [154]. Fur-
ther analysis of cell lines and patient samples would elu-
cidate such discrepancies.
Urogenital tumors
TGF-β is a crucial molecule in the genesis of urogenital
tumors, such as urinary bladder carcinoma, renal cell
carcinoma, ovarian and prostate cancers [155].
The TGF-β pathway is involved in urinary bladder can-
cer progression. The amount of secreted TGF-β1 corre-
lates with more aggressive phenotype of cell lines. In
addition, deregulated TGF-β signaling led to enhanced
migration and invasiveness of bladder cancer cells [156].
Silencing of TβRI expression by siRNA led to significant
inhibition of TGF-β-induced signal transduction and
thereby reduced invasiveness of bladder cancer cells
[157].
Clear cell renal cell carcinoma (CCRCC) is the most
common malignancy of the kidney; it accounts for 2-3%
of all malignant diseases in adults [158]. In CCRCC pa-
tient samples, sequential loss of TβRIII and TβRII ex-
pression was associated with renal cell carcinogenesis
and progression [155]. Cross-talk between Notch signal-
ing and TGF-β pathway contributes to aggressiveness of
CCRCC. Recently, it was described that inhibition of
Notch signaling leads to attenuation of basal TGF-β-
induced signaling in CCRCC cells; it also influenced
genes involved in cancer migration [159].
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In advanced ovarian tumors, low expression of TGF-β1
mRNA is connected to better prognosis. It was found
that TGF-β1 mRNA expression was significantly lower
in tumors of patients who had optimal surgery than in
patients with suboptimal surgery. TGF-β1 mRNA ex-
pression was also significantly lower in tumors with high
sensitivity to chemotherapeutics than in those with low
sensitivity [160].
Alterations in the TβRI gene occur in ovarian cancer
and account, at least in part, for the frequent loss of
TGF-β responsiveness of these cancer cells. Presence of
TβRI 6*A allele in about 27% of human ovarian cancers
suggests that it acts as a low penetrating tumor marker
in the development of ovarian cancer [161-163].
Mutations in the TβRII allele that cause loss or decrease
in TβRII protein level are also present, BAT-RII mutations
(mutations in polyadenine tract in exon 3) were found in
22% of ovarian tumors [161]. Although this mutation is
connected to microsatellite stability, in ovarian cancers
this association remains controversial [164].
Mutations in SMAD4 are not very common in ovarian
cancer but were reported in primary cultures or cell
lines [165]. Reduced expression or loss of SMAD4 pro-
tein leads to decreased ability to bind DNA; SMAD4 in-
activation is involved in the acquisition of a more
aggressive tumor [161].
It has been suggested that SMAD4 and SMAD3 are
involved in metastatic potential of ovarian cancers
[166,167]. In ovarian cancer cell lines, TGF-β supported
metastatic activity at least partly through activation of
MMPs [168]. Deregulation in TGF-β/SMAD4 signaling
leads to epigenetic silencing of a putative tumor sup-
pressor, RunX1T1, during ovarian carcinogenesis [169].
Recently, genome-wide screening done by ChIP-seq of
TGF-β-induced SMAD4 binding in epithelial ovarian
cancer revealed that SMAD4-dependent regulatory net-
work was strikingly different in ovarian cancer compared
to normal cells and was predictive of patients survival
[170].
Prostate cancer
In prostate cancer, high level of TGF-β1 expression is
linked to tumor progression, cell migration and angio-
genesis [171]. In some prostate cell lines, even low level
of TGF-β1 induced its own expression in an autocrine
manner. However, only in benign cells, higher concen-
tration of TGF-β1 leads to recruitment of protein phos-
phatase 2A (PP2A) by activated TβRI, which terminates
the induction of TGF-β1. On the contrary, in malignant
cells, incorrect recruitment of PP2A by TβRI is respon-
sible for protruded production of TGF-β1 [172].
When compared to other types of cancer, such as
breast and colon, down-regulation of TβRs is foundmore often than mutations in SMADs. Kim et al. com-
pared protein levels of TβRI and TβRII in benign and
malignant prostate tissues and observed that loss of
receptors expression correlated with more advanced
tumor [173]. Decreased level of receptor protein is ac-
companied with decreased mRNA expression; thereby,
loss of receptor expression is a potential mechanism to
escape the growth-inhibitory effect of TGF-β [174].
However, mutations are present in only some cases of
prostate cancer, which suggests that other mechanisms
are involved. For example, in a study by Turley et al.,
loss of TβRIII expression correlated with disease pro-
gression [175]. In some cases of prostate cancer, insensi-
tivity to TGF-β is caused by promoter methylation in
TβRI [176].
So far, mutations in SMAD2 proteins were not found
in prostate cancer. However, studies in vitro revealed that
SMAD2 functions as a tumor suppressor of prostate epi-
thelial cells. It is possible that tumor suppressor function
of SMAD2 could be lost during differentiation of normal
tissues or during prostatic carcinogenesis [177-179].
Breast cancer
In normal mammalian breast development, all TGF-βs
isoforms are functionally equivalent; they are all involved
in establishing proper gland structures and apoptosis in-
duction. However, they have distinct roles in mammary
growth regulation, morphogenesis and functional differ-
entiation [180-182].
In breast cancer, results evaluating TGF-β as a prog-
nostic factor are controversial. On the one hand, analysis
demonstrated TGF-β1 expression to be significantly
higher in patients with a favorable outcome as compared
to patients with a poor prognosis [183]. On the other
hand, several studies showed that TGF-β over-expres-
sion is related to worse outcome [184,185]. Elevation of
TGF-β has been shown to participate in breast cancer
metastasis [186].
Alterations of TGF-β signaling molecules are relatively
rare, except for TβRII down-regulation. No specific
mutations were found in the coding or in the regulatory
region of the TβRII gene promoter in breast cancer
[187,188]. However, the loss of TβRII expression has
been linked to tumor progression and metastasis, princi-
pally in HER2-negative patients [114]. In addition, resist-
ance of breast cell lines to TGF-β may be due to reduced
expression of TβRII [189]. Mutations of TβRII are rare
among breast cancer patients, while changes in receptor
expression may take part in tumor progression [187].
Opposite to TβRII, intragenic mutations occur in TβRI
and are associated with metastatic breast cancer [190].
Although the role of TβRIII remains unclear, it seems
that this receptor is a suppressor of breast cancer. Loss
of TβRIII through allelic imbalance is a frequent genetic
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increases metastatic potential; moreover, decreased
TβRIII expression correlates with decreased recurrence-
free survival in breast cancer patients [191].
Mutations in downstream signaling pathway including
SMAD proteins are not very common in breast cancer;
however, inactivating mutations or loss of expression in
SMAD4 have been described [164,192].
Tumors of the digestive tract
Gastric cancer
Resistance to TGF-β is a hallmark of gastric cancer. The
relationship between TGF-β resistance and up-regulated
level of miR-106b-25 cluster (miR-106b, miR-93, and
miR-25) has been recently elucidated [193]. The cluster
is an intronic part of the Mcm7 gene and thus is regu-
lated by E2F1. Conversely, miR-106b and miR-93 control
E2F1 expression thus establishing negative feedback that
prevents E2F1 self-activation. Over-expression of miR-
106b, miR-93 and miR-25 decreases response of gastric
cancer cells to TGF-β since they interfere with synthesis
of TGF-β downstream effectors that promote cell cycle
arrest and apoptosis, such as p21CIP1 and BIM, respect-
ively [193] (Figure 5).
Mutations in TβRII that lead to insensivity of cell lines
to TGF-β mediated growth inhibition have been previ-
ously described [194]. It has been shown that conditional
loss of TGF-β signaling due to dominant negative muta-
tion in TβRII leads to increased susceptibility to gastro-
intestinal carcinogenesis in mice [195].
Epigenetic changes in TβRI are another important
mechanism of escape from TGF-β physiological func-
tion. Hypermethylation of a CpG island in the 5' region
of the TβRI was found in 80% of gastric cancer cell lines
and 12.5% of primary tumors. Treatment with demethy-
lating agent increased expression of TβRI and transient
transfection of TβRI into TGF-β resistant cell line
restored TGF-β responsiveness [123].
Effects of TGF-β on gastric cancer invasiveness and
metastasis are mediated by activation of JNK and ERK
pathways which support expression of fascin-1, an actin-
binding protein. Moreover, signaling pathway based on
SMAD proteins is not involved in this process because
transitional repression of SMADs did not alter fascin-1
expression [196].
Nevertheless, impaired signaling based on SMAD pro-
teins also occurs in gastric cancer. Shinto et al. found a
correlation between expression level of p-SMAD2 and
patients prognosis. P-SMAD2 protein expression level
was significantly higher in patients with diffuse form of
carcinoma and metastatic tumors and is associated with
worse outcome [197]. TGF-β signaling is also abrogated
by decreased expression of SMAD3. Low or undetect-
able level of SMAD3 was observed in 37.5% of humangastric cancer tissues. In cell lines, which showed defi-
cient expression of SMAD3, introduction of SMAD3
gene led to growth inhibition caused by TGF-β [198].
Sonic hedgehog (Shh), a member of the hedgehog sig-
naling pathway, promotes invasiveness of gastric cancer
through TGF-β-mediated activation of the ALK5–SMAD3
pathway. Higher concentrations of N-Shh (human recom-
binant form of Shh) enhanced cell motility and invasive-
ness in gastric cancer cells; moreover, treatment of cells
with N-Shh led to enhanced TGF-β1 secretion, TGF-β-
mediated transcriptional response, expression of ALK5
protein and phosphorylation of SMAD3. Effect of Shh
on cell motility was not observed after treatment of
cells with anti-TGF-β blocking antibody or TGF-β1
siRNA [199].
Hepatocellular carcinoma
Reduced TβRII expression was observed in approxi-
mately 25% of hepatocellular carcinoma (HCC) patients;
this event is associated with aggressive phenotype of
HCC and intrahepatic metastasis. TβRII down-regulation
also correlated with an early recurrence time and higher
grade of tumor suggesting that TβRII down-regulation is
a late event in HCC development. In addition, TGF-β is a
tumor suppressor in the majority of HCCs expressing
TβRII [200].
Mutations in intracellular signaling components have
been observed: SMAD2 mutations occur in 5% of HCC,
while loss of SMAD4 expression was found in 10% of
HCC [201,202].
Several studies of HCC indicated that over-expression
of SMAD3 promotes TGF-β-induced apoptosis [203,204].
Pro-apoptotic activity of SMAD3 requires both input from
TGF-β signaling and activation of p38 MAPK, which
occurs selectively in liver tumor cells. SMAD3 represses
transcription of an important apoptotic inhibitor, BCL-2,
by directly binding to its promoter [203].
Therapeutic options for patients with HCC are still
limited; however, it was recently described that blocking
the TGF-β signaling pathway with LY2109761, a kinase
inhibitor of TβRI, is associated with inhibition of mo-
lecular pathways involved in neo-angiogenesis and
tumor growth. LY2109761 interrupts the cross-talk be-
tween cancer cells and cancer-associated fibroblasts,
leading to significant reduction of HCC growth and dis-
semination. Currently, LY2109761 is being tested in clin-
ical trial phase II [205-207].
Colorectal cancer
In colorectal cancer (CRC), TGF-β1 inhibits proliferation
of less aggressive tumor cells but stimulates growth of
tumor cells at later stages by autocrine manner. High
level of TGF-β1 correlates with tumor progression [208].
In colorectal cell lines, TGF-β induces proliferation by
Figure 5 The E2F1/miR-106b-25/p21 pathway. In gastric cancer, miR-106b-25 cluster is activated by E2F1 in parallel with its host gene, Mcm7.
In turn, miR-106b and miR-93 regulate E2F1 expression, establishing a miRNA negative feedback loop. Over-expressed miR-106b, miR-93, and
miR-25 inhibit the synthesis of p21CIP1 and Bim (TGF-β downstream effectors) and therefore prevent cell cycle inhibition and apoptosis.
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β, TβRI, TβRII, SMAD4, pSMAD2/3 and E-cadherin
were found to be closely related to TNM stage of CRC.
Therefore, TGF-β, TβRII, SMAD4, pSMAD2/3 and E-
cadherin come into view as valuable independent bio-
markers of prognosis in CRC patients [140].
Inactivating mutations in SMAD2 and SMAD4 are fre-
quent especially in pancreatic and colorectal carcinomas,
although they do not stand for the most frequent tumor
changes. Most of SMAD2 mutations have been found in
the MH2 protein domain, thereby preventing complex
formation with SMAD3 and SMAD4. Alterations of
SMAD2 are present in about 6% of colorectal carcinoma
cases [210]. SMAD3 mutation is a very rare event in
human solid tumors; however, a missense mutation in
SMAD3 gene (leading to reduced activity of SMAD3
protein) was found in human colorectal cell lines [211].
Inactivation of SMAD4 is a genetically late event in
gastrointestinal carcinogenesis. It was identified with less
frequency in advanced colon cancers and in 16% of
colon carcinomas [212,213]. Nevertheless, recent studies
revealed that some of the TGF-β induced pathways are
SMAD4 independent [214]. Proteomic screen of SMAD4
wt and SMAD4 deficient cell lines detected different
protein levels in cell lines pointing to SMAD4 dependent
and independent TGF-β responses in colon carcinoma
cells [215]. Another study indicated that novel geneticvariant -4 T(10) in the SMAD4 gene promoter affects
its activity. Obtained preliminary results indicate that
SMAD4 gene promoter haplotype -462 T(14)/-4 T(10)
represents a potentially relevant genetic marker for
pancreatic and colorectal cancer [216]. This down-
stream inactivation of TGF-β signaling components
promotes colon adenoma to carcinoma progression.
Mutations of TβRII are frequent alterations of the
TGF-β signaling pathway (reviewed in [217]). They are
present in approximately 30% of CRC cases and were
reported in cancer cell lines, sporadic colon cancers and
patients with hereditary non-polyposis colorectal cancer
with microsatellite instability and in a smaller percentage
in microsatellite stable cancers [123,218,219]. TβRII
mutations occur in >90% of microsatellite unstable
(MSI) colon cancers and most principally affect a polya-
denine tract in exon 3 of TβRII, the BAT-RII; however,
non-BAT point mutations in TβRII were found with less
frequency also in microsatellite stable cancers [164,219].
Interestingly, it has been recently published that restor-
ation of TβRII in cancer cell lines with microsatellite in-
stability (MSI), bearing mutated TβRII, promoted cell
survival and motility. Therefore, it is plausible that such
mutations contribute to favorable outcome in MSI
patients [220].
In contrast to TβRII, mutations in TβRI are less com-
mon. They are rare in colon as well as pancreatic cancer.
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higher risk of colon cancer development [221]. Recently,
it has been described that TβRIII mRNA expression is
not significantly altered in human colorectal cell lines;
however, protein levels of TβRIII are frequently
increased, suggesting a distinct role for TβRIII in colon
cancer. Thus, enhanced expression of TβRIII is possibly
involved in cancer progression [222].
Other mechanisms, such as crosstalk between TGF-β
and Wnt/β-catenin pathways, are involved in colon cancer
progression [214]. It has been shown that SMAD4 restor-
ation is associated with suppression of Wnt/β-catenin
signaling activity, decrease of β-catenin/Tcf target genes
expression and with induction of functional E-cadherin
expression [223].
Recently, the role of microRNA in colon cancer has
been established. Elevated levels of miR-21 and miR-31
promote motility and invasiveness of colon cancer cell
line and enhance the effect of TGF-β. It seems that miR-
21 and miR-31 act as downstream effectors of TGF-β
[224].Pancreatic cancer
Pancreatic cancer has the poorest prognosis among GI
cancers due to aggressiveness, frequent metastases and re-
sistance to treatment. SMAD4, also called DPC4 (deleted
in pancreatic carcinomas), suggests close relationship be-
tween loss of this gene and pancreatic cancer. Mutation or
deletion of SMAD4 is a well-characterized disruption in
the TGF-β pathway – it occurs late in neoplastic progres-
sion, at the stage of histologically recognizable carcinoma.
In pancreatic cancers, SMAD4 is homozygously deleted in
approximately 30% of cases, inactivated in 20%, while al-
lelic loss of the whole 18q region was found in almost
90% of cases [225]. These mutations are present mostly in
the MH2 domain; however, missense, nonsense or frame-
shift mutations are present within the MH1 domain as
well [226,227].
Dual role of SMAD4 was established in a mouse
model. Smad4 or TβRII deletion in pancreatic epithe-
lium did not affect pancreatic development or physi-
ology. However, when activated K-Ras was present in
cells, loss of Smad4 or TβRII or Smad4 haploinsuffi-
ciency led to progression to high-grade tumors. Thus, it
is possible that Smad4 mediates the tumor inhibitory ac-
tion of TGF-β signaling, mainly in the progressive stage
of tumorigenesis [115].
In concordance with colorectal cancer, mutations in
TβRII were found in cancers with microsatellite instabil-
ity; however, mutations in TβRII and also in TβRI are
less common [217]. Frequency of mutations in TβRII is
about 4% and even less for TβRI [228]. Interestingly,
polymorphism within the TβRI gene, which is lesseffective in mediating anti-proliferative signals than wild
type, was described [229].
High level of TGF-β was found in serum of patients
with pancreatic adenocarcinoma suggesting that TGF-β
could possibly become a marker for monitoring disease
activity [230].
As previously mentioned in HCC, targeting TβRI/II
kinase activity in pancreatic cancer with the novel in-
hibitor LY2109761 also suppressed pancreatic cancer
metastatic processes. LY2109761 suppressed both basal
and TGF-β1–induced cell migration and invasion and
induced anoikis. In vivo, LY2109761, in combination
with gemcitabine, significantly reduced the tumor bur-
den, prolonged survival and reduced spontaneous ab-
dominal metastases [231].
Lung cancer
In non-small cell lung carcinoma (NSCLC), elevated ex-
pression of TGF-β correlates with disease progression
[232]. Furthermore, significantly higher serum concen-
trations of TGF-β1 cytokine were found in lung cancer
patients. Presumably, elevated expression and higher
levels of serum TGF-β represent an important prognos-
tic factor that could serve as a complementary diagnostic
test in lung cancer detection [233].
Defective expression of TβRII was observed in primary
NSCLC, where TβRII acts as a tumor suppressor.
Down-regulation of TβRII on transcriptional level could
be explained by aberrant methylation of the TβRII pro-
moter [234]. Moreover, reduced expression of TβRIII
has been found in NSCLC cells compared to normal
human bronchial epithelial cells [235].
Downstream components of TGF-β signaling path-
ways are important in NSCLC development. Jeon et al.
observed a correlation between better tumor-related
survival and absence of SMAD6. Moreover, SMAD6
contributes to lung cancer progression by limiting
TGF-β-mediated growth inhibition of cell lines, which
was proven by knockdown of SMAD6 that resulted in
increased apoptosis in lung cancer cell line [236].
TGF-β signaling is also required for lung adenocarcin-
oma (LAC) progression. In a study on LAC cell line
A549, knockdown of TβRII resulted in suppression of
cell proliferation, invasion and metastasis and induced
cell apoptosis [237].
TGF-β in hematological malignancies
Leukemia
Myeloid leukemia
TGF-β is a potent inhibitor of human myeloid leukemia
cells [238]. In acute myeloid leukemia (AML), t(8;21)
translocation results in the formation of a chimeric tran-
scription factor AML1/ETO. Jakubowiak et al. used
transient transfection assays and a reporter gene
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binding sequences and demonstrated that AML1/ETO
represses basal promoter activity function and blocks
response to TGF-β1. AML1/ETO possibly binds to
SMAD3, instead of activating TGF-β1 signaling path-
way. It represses TGF-β1-induced transcriptional activ-
ity and blocks TGF-β1 signaling, thus contributing to
leukemia genesis [239].
In addition, in AML, dominant negative mutations in
SMAD4 were found. They are characterized by a mis-
sense mutation in the MH1 domain and a frameshift
mutation in the MH2 domain of SMAD4. Mutated
SMAD4 lacks transcriptional activity [240].
The t(3;21) translocation fusion product AML1/EVI-1
likely interacts with SMAD3 through the first zinc finger
domain, represses SMAD3 activity by preventing SMAD3
from interacting with DNA, thereby repressing TGF-β-
mediated growth suppression in hematopoietic cells. This
way, AML1/EVI-1 contributes to leukemogenesis [241].
In acute promyeloytic leukemia (APL), t(15;17) trans-
location in which the retinoic acid receptor α (RARα)
gene on 17q12 fuses with a nuclear regulatory factor
PML on 15q22 results in the fusion protein PML-RARα
[242]. PML is normally found in 2 isoforms, a nuclear
isoform and a cytoplasmic isoform. Cytoplasmic isoform
is required for association of SMAD2/3 with SARA and
for the accumulation of SARA and TGF-β receptors,
resulting in SMAD phosphorylation (Figure 6). The
PML-RARα oncoprotein antagonizes with cytoplasmic
PML function by withdrawing cytoplasmic PML from
the SMAD/SARA/TβRI/TβRII complex resulting in
defects in TGF-β signaling [243].
In chronic myeloid leukemia (CML), t(9;22) (the so-
called Philadelphia chromosome) results in the forma-
tion of BCR-ABL fusion gene [244]. The fusion protein
is an active tyrosine kinase which enhances resistanceFigure 6 TGF-β signaling in APL. Cytoplasmic isoform of PML (cPML) pro
accumulation of SARA-SMAD2/3 and TGF-β receptors in early endosome. H
thus leads to impaired TGF-β signaling.of malignant cells to TGF-β-induced growth inhibition
and apoptosis. BCR-ABL protein targets AKT and tran-
scription factor FOXO3 and thus impairs the cytostatic
effect of TGF-β1 [245]. In addition, by improving protea-
somal degradation, BCR-ABL blocks TGF-β1-induced
expression of p27KIP1. Thus, BCR-ABL kinase promotes
activation of cyclin-dependent kinase and cell cycle pro-
gression [246].
In CML, expression of EVI-1, a proto-oncogene that is
expressed at very low levels in normal hematopoietic
cells, is increased. [247]. EVI-1 binds to the MH2 do-
main of SMAD3 repressing its DNA-binding ability and
transcriptional activity and this way attenuates TGF-β
signaling [248].
Moller et al. showed that BCR-ABL up-regulates TGF-β
signaling when expressed in Cos-l cells. In Cos-1 cells, the
expression of BCR-ABL up-regulates TGF-β-mediated
transcriptional activity by interaction between TβRI and
kinase domain of BCR-ABL, which leads to increased
activity of SMAD3 promoter and increased SMAD2
and SMAD3 protein expression level [249].
Lymphoid leukemia
In children T-cell acute lymphoblastic leukemia (ALL),
SMAD3 protein is absent or significantly decreased,
however SMAD3 mRNA is present in T-cell ALL and
normal T-cells at similar level. The level of SMAD3 is
decisive for the T-cell response to TGF-β. A reduction
in SMAD3 interplays with other oncogenic events, such
as alterations in the retinoblastoma pathway, to precede
T-cell leukemogenesis. It was proven that the loss of
Smad3 can work in tandem with a loss of p27KIP1, which
is also frequently altered in human T-cell ALL, to pro-
mote T-cell leukemogenesis in mice [250].
The t(12;21) translocation found in ALL generates the
TEL-AML1 chimeric protein. Loss of sensitivity to TGF-tein interacts with SMAD2/3 and SARA and is required for
owever, the PML-RARα oncoprotein physically interacts with cPML and
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TEL-AML1; it was shown that TEL-AML1 blocks the
ability of TGF-β to suppress proliferation via activation
of p27KIP1. The exact mechanism needs to be elucidated;
however, a possible alternative is that TEL-AML1, in
addition to binding SMAD3, binds co-repressors NcoR
and SIN3A and this complex is able to transcriptionally
activate the key cell cycle negative regulators, including
p27KIP1[251].
Scott et al. showed that mRNA of downstream com-
ponents of TGF-β pathway, such as p21CIP1 and
p15INK4B, are absent in ALL cell lines with high fre-
quency, while p27KIP1 mRNA levels are not reduced.
These findings suggest epigenetic silencing of TGF-β sig-
naling in molecular pathogenesis of ALL and possibly
p15INK4B and p21CIP1 are inactivated by this mechanism.
In ALL, p15INK4B mRNA absence is often connected
with promoter methylation, whereas reduced p21CIP1 ex-
pression happens independently of promoter methyla-
tion, indicating that within the same malignancy,
epigenetic silencing of TGF-β signaling is methylation-
dependent or independent [252].
In adult acute T-cell leukemia, TGF-β signaling is inacti-
vated through the activity of viral oncoprotein Tax. This
oncoprotein compromises trans-activation of TGF-β re-
sponsive promoters by inhibiting the ability of SMAD pro-
teins to mediate TGF-β-induced transcriptional activation
by interfering with transcriptional factor CBP/p300 [253].
Another model of its function is that Tax interacts with
the MH2 domains of SMADs 2, 3 and 4 in order to inhibit
formation of the SMAD3/4 complex, disturb the interplay
of the SMAD proteins with transcriptional factor CBP/
p300, prevent binding of the SMAD complex to its target
DNA sequence and thus inhibit TGF-β signaling [254].
The Tax repressor effect is mediated by activating JNK
leading to increased phosphorylation of c-Jun, which is
followed by formation of SMAD3/c-Jun complex that
inhibits the ability of SMAD3 to bind DNA [255].
In hairy-cell leukemia (HCL), higher levels of TGF-β1
were observed in bone marrow (BM), serum and plasma
from peripheral blood. The main source of this cytokine
in active and latent form is hairy cell (HC). HCs produce
TGF-β1, which is stored in BM near bone marrow fibro-
blasts; it activates them to synthesize collagen and re-
ticulin fibers. TGF-β1 is important in fibrosis and is
directly involved in the pathogenesis of BM reticulin fi-
brosis in HCL [256].
Lymphoma
Peripheral and cutaneous T-cell lymphoma
In cutaneous T-cell lymphoma and Sézary syndrome,
reduced levels of TβRI and TβRII correlate with de-
crease in TβRI and TβRII mRNA levels. This leads to
the loss of TGF-β growth inhibitory responses [257].Knaus et al. detected a single point mutation (Asp-
404-Gly [D404G]) in the kinase domain of TβRII in
advanced lymphoma. This dominant negative mutation
prevents cell surface expression of normal TβRII. The
ability of the mutant receptor to prevent function of
normal TGF-β receptors is a new mechanism for loss of
responsiveness to the TGF-β in tumorogenesis. Since
TβRI is not able to bind TGF-β in the absence of TβRII,
no TβRI is detected on the surface of these cells. This
mutant receptor binds to normal receptor in an intracel-
lular compartment, likely the endoplasmic reticulum,
and blocks development of the normal receptor on the
cell surface [258]. In addition, a 178-bp deletion in exon
1 in the gene for TβRI was reported to be responsible
for loss of TβRI expression on the cell surface in ana-
plastic large cell lymphoma cell line JK. This deletion
was confirmed to be present also in patients’ samples.
Also, loss of TβRI is followed by loss of its tumor sup-
pressive properties in human T-cell lymphoma [259].Non-Hodgkin´s lymphomas (NHL)
ATL, adult T-cell leukemia/lymphoma is a rare form of
Non-Hodgkin’s lymphoma (NHL). Zinc-finger E-box
binding homeobox 1 (ZEB1) is a candidate tumor sup-
pressor gene since mRNA of ZEB1 was found to be
down-regulated in ATL. Physiologically, ZEB1 binds
phosphorylated SMAD2/3 to enhance TGF-β signaling,
and it can counteract the SMAD7-mediated inhibition
of TGF-β1 function. Down-regulation of ZEB1 mRNA
together with over-expression of inhibitory SMAD7
mRNA in ATL leads to loss of responsiveness to TGF-β-
mediated growth arrest. Therefore, ZEB1 has an import-
ant role in regulation of TGF-β1 signaling pathway by
binding to R-SMADs and also I-SMADs [260].
SMAD1 protein level is elevated and it is phosphory-
lated in response to TGF-β1 signaling in NHL. This sug-
gests a role of SMAD1 in mediating the effects of TGF-β
in NHL [261].
In B-cell lymphoma, Bakkebo et al. found that phos-
phorylation of SMAD1/5 is surprisingly an important
event for the TGF-β-mediated anti-proliferative effects.
TβRI was highly expressed in these cells and likely is im-
portant for signaling through SMAD1/5 pathway. Also,
the regulation of TGF-β-mediated proliferation is at least
partly dependent on activated p38 MAPK [262]. In B-
cell lymphoma, the cell line resistant to TGF-β1 did not
possess functional TβRII. This led to the absence of nu-
clear translocation of phosphorylated SMAD3 and
SMAD2, the lack of nuclear expression of p21CIP1 and
the down-regulation of c-Myc. Chen et al. found that
methylation of promoter (CpG methylations at −25 and
−140) plays an important role in TβRII gene silencing
[263].
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which is over-expressed in aggressive type of B-cell
lymphoma, targets SMAD5 by binding to the 30 UTR of
the SMAD5 gene. Treatment of DLBCL cell line with
TGF-β1 resulted in phosphorylation of SMAD2/3 but
also of SMAD1/5 indicating an active non-canonical sig-
naling. Over-expression of miR-155 in this cell line sig-
nificantly limited the cytostatic effect of cytokine due to
impaired TGF-β1-mediated induction of p21CIP1. In
miR-155-overexpressing and SMAD5 knockdown
DLBCLs, the disruption of p21CIP1 induction was inde-
pendent of the inhibitory effects of TGF-β1 thus creating
a link between miR-155, TGF-β pathway and lymphoma-
genesis [264].
In small lymphocytic lymphoma/chronic lymphocytic
leukemia (SLL/CLL), the CLL cells are resistant to the
growth-inhibitory effects of TGF-β in spite of TβRII ex-
pression which is similar as in normal B cells. Therefore,
the loss of responsiveness to TGF-β is most likely due to
altered binding of TGF-β to the receptor complex or
downstream signaling pathway [265].Figure 7 TGF-β signaling in the bone marrow microenvironment of m
which influence cells of bone marrow microenvironment such as osteoblas
proliferation and activation.Lagneaux et al. attributed the loss of responsiveness of
CLL cells to TGF-β especially to decreased cell-surface
expression of TβRI. CLL cells resistant to TGF-β1
showed no surface TβRI able to bind TGF-β1, but the
expression of TβRII was normal. On the other hand,
both TGF-β1-sensitive and TGF-β1-resistant CLL cells
contained normal levels of TβRI and TβRII mRNAs.
The absence of functional TβRI on the surface of CLL
cells, in spite of normal mRNA level, could be explained
by point mutations in the TβRI gene [266,267].
In CLL, Schiemann et al. found mutations in the sig-
nal sequence of TβRI (Leu12Gln substitution together
with an in-frame single Ala deletion) which leads to
reduced gene transcription stimulated by TGF-β [268].
In addition, CLL cells exhibited an increased expression
of the TGF-β co-receptor, TβRIII, which is normally
not expressed entirely in hematopoietic cells [269]. On
the other hand, Lotz et al. found over-expression of
TGF-β in CLL cells; all primary cells in this study were
sensitive to the growth-inhibitory effects of this cyto-
kine [270].ultiple myeloma. Myeloma cells are able to produce TGF-β cytokine
t progenitors, bone marrow stromal cells. Moreover, it disrupts T cell
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is associated with transcriptional repression of the E2F-1
gene. On the other hand, over-expression of the E2F-1
gene overcomes the TGF-β-mediated G1 arrest. So, the
transcriptional repression of the E2F-1 gene is required
for growth arrest suggesting that TGF-β can effectively
exert tumor suppression also in cells without c-Myc,
p15INK4B and p21CIP1 regulation [271]. Inman and Allday
reported that in Burkitt´s lymphoma, cells express nor-
mal levels of TβRI RNA and protein, but decreased
levels of TβRII RNA, leading to lack of responsiveness
to TGF-β1 [272].
Multiple myeloma
In multiple myeloma (MM), higher levels of TGF-β are
secreted by myeloma cells as well as bone marrow stro-
mal cells (BMSC). TGF-β secretion escalates with the
stage of B cell differentiation (Figure 7). Increased pro-
duction of TGF-β is followed by increased interleukin-6
(IL-6) and vascular endothelial growth factor (VEGF) se-
cretion by BMSC, related to tumor cell proliferation.
TGF-β is the major inducer of IL-6 and VEGF, two im-
portant cytokines of MM. On the other hand, TGF-β
inhibits proliferation and Ig secretion of normal B cells
[273].
After treatment with TβRI kinase inhibitor (SD-208),
decreased production of IL-6 and VEGF and also attenu-
ated tumor cell growth was observed. Mechanism of ac-
tion of SD-208 is blocking nuclear accumulation of
SMAD2/3 and related production of IL-6. This leads to
inhibition of MM cell growth, survival, drug resistance
and migration [274].
In MM, no mutations in TβRI or TβRII genes were
described; MM cells contain TβRI and TβRII proteins in
the cytoplasm. Resistance to the growth-inhibitory func-
tions of TGF-β signaling develops, possibly due to de-
fective trafficking of TβRI and TβRII to the cell surface
in these cells [275,276]. Possibly, the loss of TβRII ex-
pression on the cell surface is the result of gene silencing
by hypermehylation correlating to poor survival [277].
TβRIII expression is diminished on mRNA and protein
level in MM, enhancing cell growth, proliferation, mobil-
ity, heterotrophic cell–cell adhesion and contributing to
disease progression [278].
Serum level of TGF-β is an important prognostic fac-
tor in MM. Higher levels of this cytokine mean lower
levels of normal Ig resulting in immune impairment
[279]. TGF-β secreted from MM cells disrupts prolifera-
tion, activation and IL-2 responsiveness in T cells. TGF-β
is important in this immune-suppression, and its intensity
of suppression is tumor burden dependent [280].
In MM patients, TGF-β represses bone formation in
bone lesions. Initially, TGF-β enhances proliferation of
osteoblast progenitors and promotes mineralization of bonematrix. Then, TGF-β inhibits subsequent phases of dif-
ferentiation of osteoblasts and represses mineralization
of matrix. This effect can be abrogated by inhibitors of
TβRI kinase domain (reviewed in [281]).
Conclusion
TGF-β signaling is complex and finely regulated funda-
mental pathway, which has an important role during
human development and adult life. It is broadly inter-
twined with other signaling pathways. Moreover, it is
involved in cancerogenesis of solid tumors as well as
hematological malignancies. Paradoxically, TGF-β is
both a tumor suppressor and tumor promoter. The
tumor suppressor activities are widely described as
anti-proliferative and apoptotic effects. During cancer
progression, tumor frequently avoids tumor suppressive
activities of TGF-β either by acquiring mutations of sig-
naling components or by inhibiting its anti-proliferative
response. This ’switch’ helps the tumor to use TGF-β as
an oncogenic factor inducing tumor motility, invasion,
metastasis and epithelial-to-mesenchymal transition.
Advances in the study of molecular mechanisms that elu-
cidate oncogenic activities of TGF-β lead to a strong de-
sire to target TGF-β signaling in cancer therapy.
However, the exact mechanisms involved in the malig-
nant transformation of TGF-β needs to be clarified. Only
then, it will be possible to develop successful therapeutic
strategies as well as provide new therapeutic targets to
restore the normal TGF-β function.
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